系统免疫治疗在高危BCG初治非肌层浸润性膀胱癌中的演变
法国泌尿外科学会癌症委员会对2003至2025年间37篇文献进行叙述性综述,聚焦BCG初治高危NMIBC患者中系统免疫联合膀胱内BCG的III期试验。CREST和POTOMAC研究分别显示无事件生存和无病生存的统计学显著且临床意义的改善。其他研究结果预计2025至2030年公布。
要点
- 五项III期试验评估系统免疫联合BCG治疗BCG初治高危NMIBC。
- CREST和POTOMAC研究分别达到无事件生存和无病生存显著改善。
- 联合策略可能成为BCG初治高危NMIBC的新治疗选择。
核心结论
- 系统免疫联合膀胱内BCG正在研究中,可能成为BCG初治高危NMIBC的新治疗策略。
研究设计与样本
- 法国泌尿外科学会癌症委员会协作的叙述性文献综述,纳入2003至2025年间发表的37篇参考文献。
主要发现
- 五项正在进行的III期随机、多中心、多国、开放标签研究:CREST、ALBAN、POTOMAC、KEYNOTE-676和SunRISe-3。
- CREST和POTOMAC研究分别显示无事件生存和无病生存的统计学显著且临床意义的改善。
- 其他研究结果预计2025至2030年间公布。
关键数值与推荐
- CREST研究评估sasanlimab(NCT04165317),ALBAN评估atezolizumab(NCT03799835)。
- POTOMAC研究评估durvalumab(NCT03528694),KEYNOTE-676评估pembrolizumab(NCT03711032)。
- SunRISe-3研究评估cetrelimab(NCT05714202),联合BCG或TAR-200。
临床怎么用
- 目前系统免疫联合BCG仍处于研究阶段,尚未成为BCG初治高危NMIBC的标准治疗。
局限性
- 本综述为叙述性综述,非系统评价。
- 多数III期试验结果尚未公布,需等待2025至2030年数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Treatment options for high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) are still limited. The addition of systemic immunotherapy to intravesical bacillus Calmette-Guérin (BCG) instillations is currently being explored as an initial strategy for BCG-naïve HR NMIBC patients to enhance treatment effectiveness and decrease the risk of BCG failure. METHODS: A collaborative narrative review of the literature by the Cancer Committee of the French Association of Urology (CC-AFU) was carried out to describe ongoing studies assessing systemic immunotherapy in BCG-naïve HR NMIBC patients, focus on the different study designs, and evaluate the clinical pertinence of the endpoints. In total, 37 references published between 2003 and 2025 were included in our review. KEY FINDINGS AND LIMITATIONS: The ongoing phase 3 trials in BCG-naïve HR NMIBC patients include CREST (sasanlimab; NCT04165317), ALBAN (atezolizumab; NCT03799835), POTOMAC (durvalumab; NCT03528694), KEYNOTE-676 (pembrolizumab; NCT03711032), and SunRISe-3 (cetrelimab; NCT05714202). These five randomized, multicenter, multinational, open-label studies are evaluating the efficacy and safety of systemic intravenous or subcutaneous immunotherapy in combination with intravesical BCG, or in combination with TAR-200 in SunRISe-3, compared with BCG alone in BCG-naïve HR NMIBC patients. Recently, the CREST and POTOMAC studies demonstrated statistically significant and clinically meaningful improvements in event-free and disease-free survival, respectively, heralding a new therapeutic era in this field. Other results from these studies are expected between 2025 and 2030. CONCLUSIONS AND CLINICAL IMPLICATIONS: The combination of systemic immunotherapy with intravesical BCG instillations is being investigated and may become a new therapeutic strategy for BCG-naïve HR NMIBC.
引用
- Gabriel PE, Roumiguié M, Marcq G, et al. The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer: At the Edge of a Tsunami? Eur Urol Oncol. 2025. PMID: 40752989. doi:10.1016/j.euo.2025.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。